In recognition of a public health issue that affects more than half a billion people worldwide, 1 the World Health Assembly has designated July 28 as World Hepatitis Day. 2 Every year, this day will challenge the world to meet the urgent need for prevention and control of viral hepatitis and to ensure the best possible care and treatment for those infected.
Read Article >
Educational Webcast and Video Podcast of a selection of presentations of the AASLD/CDC SINGLE TOPIC CONFERENCE - Chronic Viral Hepatitis – Strategies to Improve Effectiveness of Screening and Treatment that was held in Atlanta in June 2011
http://www.multiwebcast.com/aasld/2011/cdc.aasld.stc.hepatitis/welcome >
The ads began popping up this spring. An aging rocker, guitar in hand, peers from a poster mounted inside MBTA buses. "I survived disco,'' the text reads. "I can fight hepatitis C.
Read Article >
Dr. John Ward, director of CDC's Division of Viral Hepatitis, provided information about hepatitis as a guest on NPR's Talk of the Nation.
Read More >
The use of telemedicine to link primary caregivers to the specialized medical resources of an academic medical center proved to be extremely effective for treating chronic hepatitis C in rural and underserved regions, according to a report published online June 1 in the New England Journal of Medicine.
Read Article >
ABC 7 Chicago, in recognition of Asian/Pacific American Heritage Month, presents a half-hour special. The second half features Dr. Karen Kim's work on Hepatitis B.
Watch Video >
The U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.
Read More >
The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C. Victrelis is approved for use in combination with peginterferon alfa and ribavirin.
Read More >
The U.S. Department of Health and Human Services today launched its action plan to prevent and treat viral hepatitis, a silent epidemic affecting 3.5 – 5.3 million Americans.
Read More >
Nationwide, rates of acute, symptomatic HCV infection declined during 1992-2005 and then began to level. Declines also were observed in rates of newly reported HCV infection in Massachusetts. Although these declines were evident among reported cases overall in Massachusetts during 2002-2006, an increase was observed among cases in the 15-24 year age group. In response to this increase, the Massachusetts Department of Public Health launched a surveillance initiative to collect more detailed information on cases reported during 2007-2009 among this younger age group and to examine the data for trends through 2009. The findings indicate the need for enhanced surveillance of HCV infection and intensified hepatitis C prevention efforts targeting adolescents and young adults.
Read Article >